{
  "docId": "019dd923-622c-750b-8b9a-648c05e927ed",
  "docSlug": "ea3395f0d3bd",
  "documentTitle": "Inspire Medical Systems, Inc. (INSP)",
  "authorId": "60_Wolfpack_Research",
  "authorName": "Wolfpack Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2020-04-22 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 18,
  "pageCount": 57,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "competitive_analysis",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a quote from the CEO and images of competing medical devices.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "photo",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-648c05e927ed/18",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-648c05e927ed",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-648c05e927ed.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-648c05e927ed#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The introduction of direct competition will put pressure on Inspire's ASP and inherently reduce Inspire's realistic commercial opportunity.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-5375-7572-b873-c6bf19366573",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.73,
        "x": 0.135,
        "y": 0.365
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dae71f24-0e9b-40d5-b2fe-955c1293c2c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.775,
        "x": 0.118,
        "y": 0.285
      },
      "kind": "paragraph",
      "text": "There are similar surgically implanted OSA treatments working towards FDA and Medicare approval, such as LivaNova’s “Aura 6000” device and Nyxoah’s “Genio System” which already received CE Mark approval in Europe. The introduction of direct competition will put pressure on Inspire’s ASP and inherently reduce Inspire’s realistic commercial opportunity.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e89f2ce-5871-4584-a22b-079a3ebdedc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.775,
        "x": 0.118,
        "y": 0.143
      },
      "kind": "paragraph",
      "text": "When Inspire was launched, it was not a new concept and it did not use game-changing technology. Medtronic had first tried hypoglossal nerve stimulation back in the late ‘90s. Their first patents were filed in 1998, nearly a decade before Inspire was spun off from Medtronic. Inspire’s CEO, Tim Herbert, acts obnoxiously confident about this perceived lack of competition:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6520111-3bcc-4162-bb5c-b1e9cd8d424a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.725,
        "x": 0.168,
        "y": 0.223
      },
      "kind": "quote",
      "text": "So, we don't have competition -- it's not like we're grabbing market share. It's our market to create. So this is the what keeps me up at night. It's the question -- it's about how do we stay in control while we're growing fast.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebaf2f67-1882-44f4-b71b-3cc7c23e39d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"So, we don't have competition -- it's not like we're grabbing market share. It's our market to create. So this is the what keeps me up at night. It's the question -- it's about how do we stay in control while we're growing fast.\" — Tim Herbert, Inspire's CEO",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-5375-7572-b873-c8573077f8b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.63,
        "x": 0.185,
        "y": 0.785
      },
      "kind": "source-note",
      "text": "Inspire Medical, Respicardia, LivaNova, and Nyxoah share the latest data on their devices.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ee768b8-dd9e-4881-a41e-f011a658055e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.118,
        "y": 0.865
      },
      "kind": "source-note",
      "text": "36 RBC Capital Markets Healthcare Conference, May 22, 2019, accessed via Bloomberg, LP\n37 Average selling price\n38 http://www.sleepreviewmag.com/2019/05/neurostimulators-sleep-apnea/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3f18a3d-9a1c-43c8-b03d-17ab9676f9f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.585,
        "x": 0.118,
        "y": 0.111
      },
      "kind": "title",
      "text": "4. Cheaper, Less Invasive Competition is Growing Quickly:",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60a4f00f-42c4-4410-b0c0-6e693b57959d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 6,
      "beatId": "e9079ce5-c7de-4121-8615-3ae679f7ffcd",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "The document presents the limitations and side effects of the product",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 14,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "83735121-ef20-47de-bdeb-a1fe30c3f52e",
      "evidence": "The document presents an alternative to CPAP that is effective and minimally invasive",
      "position": 1,
      "objective": "To highlight the cost of inaction for investors",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}